X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Torrent Pharma Fact Sheet, Torrent Pharma Financial Results - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Torrent Pharma Fact Sheet   (TORR)

Here is the latest financial fact sheet of Torrent Pharma. For more details, see the Torrent Pharma quarterly results and Torrent Pharma share price and chart. For a sector overview, read our pharmaceuticals sector report.

TORRENT PHARMA Price History

Price Rs 1,322.7
Mkt Cap Rs m 223,880
Vol '000 7.4
P/E X 27.1
P/CF X 18.0
EPS (TTM) Rs 48.9
% ch % -2.6
No. of shares m 169.26
% ch week % -6.7
% ch 1-mth % -8.9
% ch 12-mth % 1.2
52 week H/L Rs 1,572.1/1,143.5
(As on Feb 22, 2018 (Close))
* Results Consolidated
Excel EXPORT | DO YOU LIKE THESE FACTSHEETS? TELL US!

TORRENT PHARMA Financials

No. of Mths
Year Ending
12
Mar-13
*
12
Mar-14
*
12
Mar-15
*
12
Mar-16
*
12
Mar-17
*
5-Yr Chart
Click to enlarge
TORRENT PHARMA EQUITY SHARE DATA
High Rs7675781,2321,7201,768 
Low Rs5973345231,1341,186 
Sales per share (Unadj.) Rs379.5247.3275.0394.5346.1 
Earnings per share (Unadj.) Rs51.139.244.4102.455.2 
Diluted earnings per shareRs25.639.244.4102.455.2 
Cash flow per share (Unadj.) Rs60.944.455.6116.573.3 
Dividends per share (Unadj.) Rs23.0010.0011.2540.0014.00 
Adj. dividends per shareRs11.5010.0011.2539.9914.00 
Dividend yield (eoy) %3.42.21.32.80.9 
Book value per share (Unadj.) Rs168.1112.4156.2206.5257.1 
Adj. book value per shareRs84.0112.4156.1206.4257.0 
Shares outstanding (eoy) m84.61169.22169.22169.22169.22 
Bonus/Rights/Conversions  -B1:1--- 
Price / Sales ratio x1.81.83.23.64.3 
Avg P/E ratio x13.311.619.813.926.8 
P/CF ratio (eoy) x11.210.315.812.320.1 
Price / Book Value ratio x4.14.15.66.95.7 
Dividend payout %45.025.525.439.125.4 
Avg Mkt Cap Rs m57,70477,190148,465241,435249,887 
No. of employees `0009.69.511.010.911.8 
Total wages/salary Rs m6,2337,4118,4188,4249,934 
Avg. sales/employee Rs Th3,354.04,386.54,212.46,129.64,971.5 
Avg. wages/employee Rs Th651.0776.8762.0773.4843.2 
Avg. net profit/employee Rs Th452.0695.9679.81,591.3792.4 
TORRENT PHARMA INCOME DATA
Net Sales Rs m32,11141,84746,53566,76458,569 
Other income Rs m4343812,8562,2562,233 
Total revenues Rs m32,54542,22949,39069,02060,802 
Gross profit Rs m6,9229,51510,20227,33013,773 
Depreciation Rs m8278701,9072,3763,069 
Interest Rs m3385861,7521,8402,056 
Profit before tax Rs m6,1918,4409,39825,37110,881 
Minority Interest Rs m-220000 
Prior Period Items Rs m00000 
Extraordinary Inc (Exp) Rs m-37500-1,9360 
Tax Rs m1,4671,8011,8886,1021,545 
Profit after tax Rs m4,3286,6397,50917,3339,336 
Gross profit margin %21.622.721.940.923.5 
Effective tax rate %23.721.320.124.114.2 
Net profit margin %13.515.916.126.015.9 
TORRENT PHARMA BALANCE SHEET DATA
Current assets Rs m25,60934,04540,98346,88253,841 
Current liabilities Rs m17,10721,74627,04632,85531,612 
Net working cap to sales %26.529.430.021.038.0 
Current ratio x1.51.61.51.41.7 
Inventory Days Days10588847497 
Debtors Days Days78961257984 
Net fixed assets Rs m11,05114,09534,72039,00742,079 
Share capital Rs m423846846846846 
"Free" reserves Rs m13,63417,27225,58334,09542,655 
Net worth Rs m14,21919,02426,43034,94143,501 
Long term debt Rs m4,5457,44521,72918,50122,408 
Total assets Rs m37,83950,69879,64190,579101,250 
Interest coverage x19.315.46.414.86.3 
Debt to equity ratio x0.30.40.80.50.5 
Sales to assets ratio x0.80.80.60.70.6 
Return on assets %12.314.311.621.211.3 
Return on equity %30.434.928.449.621.5 
Return on capital %32.734.123.247.319.6 
Exports to sales %37.737.430.443.30 
Imports to sales %7.68.26.06.90 
Exports (fob) Rs m12,11415,66514,13628,9340 
Imports (cif) Rs m2,4333,4162,8014,5840 
Fx inflow Rs m13,22816,86214,26529,18520,066 
Fx outflow Rs m4,7345,1965,1846,0215,304 
Net fx Rs m8,49411,6669,08123,16514,762 
TORRENT PHARMA CASH FLOW
From Operations Rs m 1,535 5,994 8,102 27,421 10,127 
From Investments Rs m -2,417 -3,558 -21,623 -8,379 -7,869 
From Financial Activity Rs m 197 864 12,123 -14,352 -1,918 
Net Cashflow Rs m -685 3,300 -1,399 4,375 212 
* Results Consolidated
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Share Holding

Indian Promoters 71.5%
Foreign collaborators 0.0%
Indian inst/Mut Fund 7.0%
FIIs 12.6%
ADR/GDR 0.0%
Free float 8.8%
Shareholders 26,511
Pledged promoter(s) holding 0.0%
 

Company Information

REGD OFF Torrent House, Off Ashram Road, Ahmedabad - 380 009
E-MAIL maheshagrawal@torrentpharma.com WEB www.torrentpharma.com
TELEPHONE (079) 2658 5090 FAX (079) 2658 2100
SECTOR PHARMACEUTICALS GROUP MISCELLANEOUS
TR AGENT Karvy Computershare, 17-24, Vithalrao Nagar, Madhapur, Hyderabad-81
AUDITOR Deloitte Haskins & Sells
CHM: Sudhir Mehta COMP SEC: Mahesh Agarwal YEAR OF INC: 1973 BSE CODE: 500420 FV (Rs): 5 DIV YIELD (%): 1.1

More Pharmaceuticals Company Fact Sheets:   ORCHID PHARMA LTD  LUPIN LTD  ELDER PHARMA  PLETHICO PHARMA  J.B.CHEMICALS  

Compare TORRENT PHARMA With:   ORCHID PHARMA LTD  LUPIN LTD  ELDER PHARMA  PLETHICO PHARMA  J.B.CHEMICALS  

Compare TORRENT PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices End Day Flat; Oil and Gas Stocks Lead Losses(Closing)

After opening the day in red, share markets in India witnessed negative trading activity throughout the day and ended the day on a weak note.

Views on news

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

TRACK TORRENT PHARMA

  • Track your investment in TORRENT PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON TORRENT PHARMA

TORRENT PHARMA - SUN PHARMA COMPARISON

COMPARE TORRENT PHARMA WITH

MARKET STATS